Diamedica Therapeutics Inc Stock Ownership - Who owns Diamedica Therapeutics?

Insider buying vs selling

Have Diamedica Therapeutics Inc insiders been buying or selling?
Jan Stahlberg10% Owner2024-06-281,200,000$2.50
Koch Thomas Von10% Owner2024-06-281,200,000$2.50
James T. ParsonsDirector2024-01-0221,428$2.80
Richard D. PilnikDirector2024-01-0230,357$2.80
Charles Pauling SembaDirector2024-01-029,375$2.80
Randall Michael GiuffreDirector2024-01-0219,196$2.80
Richard KuntzDirector2024-01-0214,285$2.80
David J. WambekeChief Business Officer2023-11-1620,000$2.46

1 of 1

DMAC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DMAC insiders and whales buy or sell their stock.

DMAC Shareholders

What type of owners hold Diamedica Therapeutics Inc stock?
Koch Thomas Von29.05%11,030,155$35.96MInsider
Jan Stahlberg24.35%9,243,216$30.13MInsider
Richard Jacinto Ii12.01%4,558,823$14.86MInsider
Vanguard Group Inc2.67%1,013,522$3.30MInstitution
Zhenyu Xiao2.65%1,007,100$3.28MInsider
Cooperman Leon G2.33%883,623$2.88MInstitution
First Manhattan Co LLC2.24%850,038$2.77MInstitution
David J. Wambeke1.39%527,114$1.72MInsider
Paragon Associates Paragon Associates Ii Joint Venture1.32%500,000$1.63MInstitution
Randall Michael Giuffre1.29%490,953$1.60MInsider

1 of 3

DMAC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DMAC12.11%72.36%Net BuyingNet Buying
NVCT8.51%49.77%Net BuyingNet Buying
RLMD47.42%3.43%Net Buying

Diamedica Therapeutics Stock Ownership FAQ

Who owns Diamedica Therapeutics?

Diamedica Therapeutics (NASDAQ: DMAC) is owned by 12.11% institutional shareholders, 72.36% Diamedica Therapeutics insiders, and 15.52% retail investors. Koch Thomas Von is the largest individual Diamedica Therapeutics shareholder, owning 11.03M shares representing 29.05% of the company. Koch Thomas Von's Diamedica Therapeutics shares are currently valued at $35.85M.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.